Výsledky vyhledávání - "Sarah E. Donegan"

A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA)

Autor: Stephan Hois, Feng Xiao, Sarah E. Donegan, Hiroyuki Nishiyama, Matthew D. Galsky, Erik T. Goluboff, Joshua J. Meeks, Hikmat Al-Ahmadie, Vanessa Williams, Michiel S. van der Heijden, James W.F. Catto, Thomas Powles

Publikováno v: Journal of Clinical Oncology. 39:TPS505-TPS505

TPS505 Background: Management of muscle-invasive bladder cancer (MIBC) includes both surgery and systemic therapy. Neoadjuvant cisplatin-based combination chemotherapy has demonstrated improved pathologic complete response (pCR), event-free survival

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ef58280fe5862083a3a7bcbfba99ff00
https://doi.org/10.1200/jco.2021.39.6_suppl.tps505

Zobrazit plný text záznamu

A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine+cisplatin (G+C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA)

Autor: Thomas Powles, Joshua J Meeks, Matt D. Galsky, Michiel Simon Van Der Heijden, Hiroyuki Nishiyama, Hikmat Al-Ahmadie, Ashok Kumar Gupta, Jiabu Ye, Sarah E. Donegan, Dana C. Ghiorghiu, Salvatore Ferro, James WF Catto

Publikováno v: Journal of Clinical Oncology. 37:TPS4592-TPS4592

TPS4592 Background: Management of MIBC includes both surgery and systemic therapy. Neoadjuvant, cisplatin-based combination chemotherapy has demonstrated improved pathologic complete response (pCR), event-free survival (EFS), and OS compared with rad

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e06a9354fe53c9b77739bd5738002245
https://doi.org/10.1200/jco.2019.37.15_suppl.tps4592

Zobrazit plný text záznamu

Novel treatment for the management of ifosfamide neurotoxicity: Rationale for the use of methylene blue

Autor: Sarah E. Donegan

Publikováno v: Journal of Oncology Pharmacy Practice. 6:153-165

Objective. To provide an overview of the proposed pathophysiology of ifosfamide encephalopathy and the role of methylene blue for the treatment and prevention of this toxicity. Data Source. A Medline search using the terms ‘‘ifosfamide encephalop

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cbe6d835308602bb327d972994524e0
https://doi.org/10.1177/107815520100600404

Zobrazit plný text záznamu

Abrogation of the Hematological and Biological Activities of the Interleukin-3/Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein PIXY321 by Neutralizing Anti-PIXY321 Antibodies in Cancer Patients Receiving High-Dose Carboplatin

Autor: Brendan D. Curti, Walter J. Urba, Barry L. Gause, John E. Janik, Edward L. Korn, Sarah E. Donegan, Langdon L. Miller, John W. Smith, Dan L. Longo, Thelma M. Watson, Diane Stevens, Mario Sznol, William C. Kopp, Jon Holmlund

Publikováno v: Blood. 93:3250-3258

This dose-escalation study was performed to evaluate the hematologic activity, biological effects, immunogenicity, and toxicity of PIXY321 (an interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein) administered after high-dose

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b11eb8a44c25458183b818a74b08604f
https://doi.org/10.1182/blood.v93.10.3250.410k35_3250_3258

Zobrazit plný text záznamu

Epidermal growth factor receptor inhibitors: a novel anticancer therapy

Autor: Karen M. Naples, Sarah E. Donegan

Publikováno v: Cancer practice. 10(1)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5482155c06c6df0dad42762673d4924
https://pubmed.ncbi.nlm.nih.gov/11866711

Zobrazit plný text záznamu

Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients

Autor: William C. Kopp, Paige Kostboth, Dan L. Longo, Diane Stevens, Barry L. Gause, Sarah E. Donegan, Brendan D. Curti, Langdon L. Miller, Robert Ullrich, Dennis D. Taub, Harry D. Dawson, John E. Janik, Barbara K. Dunn, Kevin C. Conlon, W. Gregory Alvord

Publikováno v: Clinical immunology (Orlando, Fla.). 93(3)

Dendritic cells (DCs) initiate primary and stimulate secondary T-cell responses. We conducted a phase I trial of tumor necrosis factor (TNF-alpha) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with cancer to increase DCs i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2493bfeaec839e4c78dd0ac5e83afd05
https://pubmed.ncbi.nlm.nih.gov/10600331

Zobrazit plný text záznamu

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance

Autor: John C. Byrd, Thomas J. Maneatis, Frank T. Ward, Sarah E. Donegan, Timothy Murphy, Melissa A. Sipe, Brian P. Monahan, Christine A. White, Jamie K. Waselenko

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 17(3)

PURPOSE: Rituximab was recently approved for use in relapsed, low-grade non-Hodgkin's lymphoma; however, few data exist regarding the safety of this agent in patients with a high number of tumor cells in the blood. METHODS AND RESULTS: After the obse

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e124029e421d2aa361f467aa49edc882
https://pubmed.ncbi.nlm.nih.gov/10071268

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání